| 4.07 0.05 (1.24%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.76 | 1-year : | 5.56 |
| Resists | First : | 4.07 | Second : | 4.76 |
| Pivot price | 3.97 |
|||
| Supports | First : | 3.72 | Second : | 3.5 |
| MAs | MA(5) : | 3.98 |
MA(20) : | 3.95 |
| MA(100) : | 3.57 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0  |
| %K %D | K(14,3) : | 65.7 |
D(3) : | 60.5 |
| RSI | RSI(14): 62.7 |
|||
| 52-week | High : | 4.07 | Low : | 2.29 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PYPD ] has closed above the upper band by 7.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 58.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.08 - 4.09 | 4.09 - 4.1 |
| Low: | 3.96 - 3.98 | 3.98 - 4 |
| Close: | 4.04 - 4.07 | 4.07 - 4.09 |
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Tue, 16 Dec 2025
PolyPid Ltd. Appoints Brooke Story as Chairman of the Board of Directors - Quiver Quantitative
Tue, 16 Dec 2025
PolyPid (Nasdaq: PYPD) appoints Brooke Story, 25-year MedTech leader, as board chair - Stock Titan
Wed, 03 Dec 2025
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission - GlobeNewswire
Thu, 13 Nov 2025
PolyPid Ltd. (NASDAQ:PYPD) Q3 2025 Earnings Call Transcript - Insider Monkey
Wed, 29 Oct 2025
PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025 - GlobeNewswire
Wed, 17 Sep 2025
Late-Stage Biopharma PolyPid Announces Double Conference Lineup: Lytham Partners and ROTH Healthcare - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 15.7 (%) |
| Held by Institutions | 38.4 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 85 (K) |
| EPS | -2.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -88 % |
| Return on Equity (ttm) | -390.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.45 |
| PEG Ratio | 0 |
| Price to Book value | 4.42 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|